Cistanche Total Glycosides (CTG) is being investigated as a potential treatment for amyotrophic lateral sclerosis (ALS), a severe neurodegenerative disease with limited treatment options. Currently, riluzole is the only FDA-approved drug for ALS, highlighting a significant unmet need in the market. If CTG demonstrates efficacy in this randomized controlled trial, it could position itself as a novel therapeutic option, potentially capturing market share in a niche but critical segment. The trial's outcomes may also attract interest from investors and partners looking to expand their portfolios in neurodegenerative diseases, particularly given the increasing prevalence of ALS and the demand for innovative treatments.